The Study on COgnition and Prognosis in the Elderly (SCOPE) - Recent analyses

Journal of Hypertension

Volumn 24, Issue SUPPL. 1, 2006, Pages

  Trenkwalder, Peter ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Angiotensin receptor blockers; Candesartan cilexetil; Cognitive function; Dementia; Elderly; Hypertension; Morbidity; Mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; LOSARTAN; PLACEBO; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ADD ON THERAPY; BACKACHE; BLOOD PRESSURE MONITORING; BRAIN ATROPHY; BRONCHITIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COGNITION; DEMENTIA; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG DOSAGE FORM; HUMAN; MINI MENTAL STATE EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; STROKE; SYSTOLIC HYPERTENSION; VERTIGO; AGED; ATROPHY; BRAIN; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; HYPERTENSION; MORTALITY; PATHOLOGY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SYSTOLE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; ATROPHY; BENZIMIDAZOLES; BRAIN; COGNITION; HUMANS; HYPERTENSION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; SYSTOLE; TETRAZOLES;

EID: 33745570098     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220415.99610.22     Document Type: Review

References (29)

1. Gradman AH. AT1-receptor blockers: differences that matter. J Hum Hypertens 2002; 16 (suppl 3):S9-S16.
2. Lacourcière Y, Asmar R. A comparison of the efficacy and duration of action of candesartan cilexetil and losartan as assessed by clinic and ambulatory blood pressure after a missed dose, in truly hypertensive patients. A placebo-controlled forced titration study. Am J Hypertens 1999;12:1181-1187.
3. Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens 2003;21:1563-1574.
4. Jandeleit-Dahm KAM, Tikellis C, Reid CM, Johnston CI, Cooper ME. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J Hypertens 2005; 23:463-473.
5. Trenkwalder P. Preventing the cardiovascular complications of hypertension. Eur Heart J 2004; 6 (suppl H):H37-H42.
6. Dahlöf B, Devereaux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al., for the Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
8. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, et al., and the Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1702.
9. Dannenberg AL, Garrison RJ, Kannel WB. Incidence of hypertension in the Framingham Study. Am J Publ Health 1988; 78:676-679.
10. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37:869-874.
11. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the elderly trial. Lancet 1985; 1:1349-1354.
12. Dahlöf B, Lindholm LH, Hansson L, Scherstén B, Ekbom T, Wester P-O. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338:1281-1285.
13. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265:3255-3264.
14. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson L-A, Nilsson L, et al. 15-Year longitudinal study of blood pressure and dementia. Lancet 1996; 347:1141-1145.
15. Forette F, Seux M-L, Staessen J, Thijs L, Birkenhäger WH, Babarskiene M-R, et al., on behalf of the Syst-Eur Investigators. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (SYST-Eur) trial. Lancet 1998; 352:1347-1351.
16. Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M, et al. Study on COgnition and Prognosis in the Elderly (SCOPE). Blood Press 1999; 8:177-183.
17. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens 2003; 21:875-886.
18. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764.
19. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. The Study on COgnition and Prognosis in the Elderly (SCOPE): outcomes in patients not receiving add-on therapy after randomisation. J Hypertens 2004; 22:1605-1612.
20. Mancia G, Seravalle G, Grassi G. Systolic blood pressure: an underestimated cardiovascular risk factor. J Hypertens 2002; 20 (suppl 5):S21-S27.
21. Franklin SS, Jacobs MJ, Wong ND, L'Italien GJ, Lapuerta P. Predominance of isolated systolic hypertension among middle-aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III. Hypertension 2001; 37:869-874.
22. Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, et al., for the Study on COgnition and Prognosis in the Elderly Study Group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on COgnition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44:1175-1180.
23. World Health Organization-International Society of Hypertension Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:151-183.
24. Trenkwalder P, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Papademetriou V, et al. The Study on COgnition and Prognosis in the Elderly (SCOPE) - major CV events and stroke in subgroup of patients. Blood Press 2005; 14:31-37.
25. World Health Organization. The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. Geneva, Switzerland: World Health Organization; 1992.
26. Jorm A, Jolley D. The incidence of dementia: a meta-analysis. Neurology 1998; 51:728-733.
27. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al., for the SCOPE Study Group. Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18:1052-1059.
28. Saxby BK, Harrington F, McKeith IG, Wesnes K, Ford GA. The effect of candesartan cilexetil on cognitive function in older adults with mild hypertension [abstract 3B.5]. J Hypertens 2003; 21 (suppl 4):S18-S19.
29. Wiseman RM, Burton EJ, Saxby BK, O'Brien JT, Ford GA. Increased brain atrophy rate in older hypertensive subjects [abstract 3B.1]. J Hypertens 2003; 21 (suppl 4):S17-S18.